株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

呼吸器合胞体ウイルス (RSV) 感染症/ヒトパラインフルエンザウイルス3型感染症の治療薬:パイプライン製品の分析

Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018

発行 GlobalData 商品コード 633179
出版日 ページ情報 英文 82 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
呼吸器合胞体ウイルス (RSV) 感染症/ヒトパラインフルエンザウイルス3型感染症の治療薬:パイプライン製品の分析 Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018
出版日: 2018年04月30日 ページ情報: 英文 82 Pages
概要

当レポートでは、呼吸器合胞体ウイルス (RSV) 感染症およびのヒトパラインフルエンザウイルス3型感染症の治療薬の治験・開発動向について分析し、疾患の概要や、現在までの治療薬の開発・上市状況、現在治験中/審査中の主要なパイプライン製品の一覧、休止中・中止済みプロジェクトの概略、今後の治験の方向性や実現見通しなどについて調査しております。

第1章 目次

第2章 イントロダクション

  • 分析範囲
  • 呼吸器合胞体ウイルス (RSV) 感染症の場合:概要
  • ヒトパラインフルエンザウイルス3型感染症の場合:概要

第3章 治療薬の開発・治験

  • 呼吸器合胞体ウイルス感染症の場合
  • ヒトパラインフルエンザウイルス3型感染症の場合

第4章 治療薬の評価

  • 呼吸器合胞体ウイルス感染症の場合
  • ヒトパラインフルエンザウイルス3型感染症の場合

第5章 医療薬の開発に参加している企業

  • 呼吸器合胞体ウイルス感染症の場合
  • ヒトパラインフルエンザウイルス3型感染症の場合

第6章 休止中のプロジェクト

  • 呼吸器合胞体ウイルス感染症の場合
  • ヒトパラインフルエンザウイルス3型感染症の場合

第7章 中断されたプロジェクト

  • 呼吸器合胞体ウイルス感染症の場合
  • ヒトパラインフルエンザウイルス3型感染症の場合

第8章 製品開発のマイルストーン

  • 呼吸器合胞体ウイルス感染症の場合

第9章 付録

図表

1.1 List of Tables

  • Table 1: Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections 9
  • Table 2: Number of Products under Development by Companies, Respiratory Syncytial Virus (RSV) Infections 11
  • Table 3: Number of Products under Development by Universities/Institutes, Respiratory Syncytial Virus (RSV) Infections 14
  • Table 4: Products under Development by Companies, Respiratory Syncytial Virus (RSV) Infections 15
  • Table 5: Products under Development by Universities/Institutes, Respiratory Syncytial Virus (RSV) Infections 20
  • Table 6: Number of Products under Development for Human Parainfluenza Virus 3 Infections 22
  • Table 7: Number of Products under Development by Companies, Human Parainfluenza Virus 3 Infections 23
  • Table 8: Number of Products under Development by Universities/Institutes, Human Parainfluenza Virus 3 Infections 24
  • Table 9: Products under Development by Companies, Human Parainfluenza Virus 3 Infections 24
  • Table 10: Products under Development by Universities/Institutes, Human Parainfluenza Virus 3 Infections 24
  • Table 11: Number of Products by Stage and Target, Respiratory Syncytial Virus (RSV) Infections 26
  • Table 12: Number of Products by Stage and Mechanism of Action, Respiratory Syncytial Virus (RSV) Infections 27
  • Table 13: Number of Products by Stage and Route of Administration, Respiratory Syncytial Virus (RSV) Infections 29
  • Table 14: Number of Products by Stage and Molecule Type, Respiratory Syncytial Virus (RSV) Infections 31
  • Table 15: Number of Products by Stage and Target, Human Parainfluenza Virus 3 Infections 32
  • Table 16: Number of Products by Stage and Mechanism of Action, Human Parainfluenza Virus 3 Infections 34
  • Table 17: Number of Products by Stage and Route of Administration, Human Parainfluenza Virus 3 Infections 36
  • Table 18: Number of Products by Stage and Molecule Type, Human Parainfluenza Virus 3 Infections 37
  • Table 19: Respiratory Syncytial Virus (RSV) Infections - Pipeline by 3-V Biosciences Inc, 38
  • Table 20: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Abivax SA 38
  • Table 21: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ablynx NV 39
  • Table 22: Respiratory Syncytial Virus (RSV) Infections - Pipeline by ADMA Biologics Inc 39
  • Table 23: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Agilvax Inc 40
  • Table 24: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Amarillo Biosciences Inc 40
  • Table 25: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Anima Biotech Ltd 41
  • Table 26: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aridis Pharmaceuticals LLC 41
  • Table 27: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Artificial Cell Technologies Inc 41
  • Table 28: Respiratory Syncytial Virus (RSV) Infections - Pipeline by AstraZeneca Plc 42
  • Table 29: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Bavarian Nordic A/S 43
  • Table 30: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Celltrion Inc 43
  • Table 31: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Curevac AG 44
  • Table 32: Respiratory Syncytial Virus (RSV) Infections - Pipeline by DBV Technologies SA 44
  • Table 33: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Enanta Pharmaceuticals Inc 45
  • Table 34: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Evec Inc 45
  • Table 35: Respiratory Syncytial Virus (RSV) Infections - Pipeline by F. Hoffmann-La Roche Ltd 46
  • Table 36: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gene Techno Science Co Ltd 46
  • Table 37: Respiratory Syncytial Virus (RSV) Infections - Pipeline by GenVec Inc 47
  • Table 38: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gilead Sciences Inc 47
  • Table 39: Respiratory Syncytial Virus (RSV) Infections - Pipeline by GlaxoSmithKline Plc 48
  • Table 40: Respiratory Syncytial Virus (RSV) Infections - Pipeline by iBio Inc 48
  • Table 41: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Immunovaccine Inc 49
  • Table 42: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Immunwork Inc 49
  • Table 43: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Inovio Pharmaceuticals Inc 50
  • Table 44: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Johnson & Johnson 51
  • Table 45: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Karyopharm Therapeutics Inc 51
  • Table 46: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Kineta Inc 52
  • Table 47: Respiratory Syncytial Virus (RSV) Infections - Pipeline by mAbxience SA 52
  • Table 48: Respiratory Syncytial Virus (RSV) Infections - Pipeline by MedImmune LLC 52
  • Table 49: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Medivir AB 53
  • Table 50: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mymetics Corp 54
  • Table 51: Respiratory Syncytial Virus (RSV) Infections - Pipeline by NanoBio Corp 54
  • Table 52: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Navigen Inc 54
  • Table 53: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Novavax Inc 55
  • Table 54: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Phoenix Biotechnology Inc 55
  • Table 55: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Profectus BioSciences Inc 56
  • Table 56: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Pulmocide Ltd 56
  • Table 57: Respiratory Syncytial Virus (RSV) Infections - Pipeline by ReViral Ltd 57
  • Table 58: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Romark Laboratories LC 57
  • Table 59: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Takeda Pharmaceutical Co Ltd 58
  • Table 60: Respiratory Syncytial Virus (RSV) Infections - Pipeline by TechnoVax Inc 58
  • Table 61: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Themis Bioscience GmbH 58
  • Table 62: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vault Pharma Inc 59
  • Table 63: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vaxart Inc 59
  • Table 64: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Virometix AG 60
  • Table 65: Respiratory Syncytial Virus (RSV) Infections - Pipeline by Visterra Inc 60
  • Table 66: Respiratory Syncytial Virus (RSV) Infections - Pipeline by VLP Biotech Inc 60
  • Table 67: Human Parainfluenza Virus 3 Infections - Pipeline by 3-V Biosciences Inc 61
  • Table 68: Human Parainfluenza Virus 3 Infections - Pipeline by Amarillo Biosciences Inc 61
  • Table 69: Human Parainfluenza Virus 3 Infections - Pipeline by Ansun Biopharma Inc 62
  • Table 70: Human Parainfluenza Virus 3 Infections - Pipeline by Moderna Therapeutics Inc 62
  • Table 71: Respiratory Syncytial Virus (RSV) Infections - Dormant Projects 63
  • Table 72: Human Parainfluenza Virus 3 Infections - Dormant Projects 67
  • Table 73: Respiratory Syncytial Virus (RSV) Infections - Discontinued Products 68
  • Table 74: Human Parainfluenza Virus 3 Infections - Discontinued Products 68

List of Figures

  • Figure 1: Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections 9
  • Figure 2: Number of Products under Development by Companies, Respiratory Syncytial Virus (RSV) Infections 10
  • Figure 3: Number of Products under Development by Universities/Institutes, Respiratory Syncytial Virus (RSV) Infections 13
  • Figure 4: Number of Products under Development for Human Parainfluenza Virus 3 Infections 22
  • Figure 5: Number of Products under Development by Companies, Human Parainfluenza Virus 3 Infections 23
  • Figure 6: Number of Products by Top 10 Targets, Respiratory Syncytial Virus (RSV) Infections 25
  • Figure 7: Number of Products by Stage and Top 10 Targets, Respiratory Syncytial Virus (RSV) Infections 25
  • Figure 8: Number of Products by Top 10 Mechanism of Actions, Respiratory Syncytial Virus (RSV) Infections 26
  • Figure 9: Number of Products by Stage and Top 10 Mechanism of Actions, Respiratory Syncytial Virus (RSV) Infections 27
  • Figure 10: Number of Products by Routes of Administration, Respiratory Syncytial Virus (RSV) Infections 28
  • Figure 11: Number of Products by Stage and Routes of Administration, Respiratory Syncytial Virus (RSV) Infections 28
  • Figure 12: Number of Products by Top 10 Molecule Types, Respiratory Syncytial Virus (RSV) Infections 29
  • Figure 13: Number of Products by Stage and Top 10 Molecule Types, Respiratory Syncytial Virus (RSV) Infections 30
  • Figure 14: Number of Products by Targets, Human Parainfluenza Virus 3 Infections 31
  • Figure 15: Number of Products by Stage and Targets, Human Parainfluenza Virus 3 Infections 32
  • Figure 16: Number of Products by Mechanism of Actions, Human Parainfluenza Virus 3 Infections 33
  • Figure 17: Number of Products by Stage and Mechanism of Actions, Human Parainfluenza Virus 3 Infections 33
  • Figure 18: Number of Products by Top 10 Routes of Administration, Human Parainfluenza Virus 3 Infections 35
  • Figure 19: Number of Products by Stage and Routes of Administration, Human Parainfluenza Virus 3 Infections 35
  • Figure 20: Number of Products by Molecule Types, Human Parainfluenza Virus 3 Infections 36
  • Figure 21: Number of Products by Stage and Molecule Types, Human Parainfluenza Virus 3 Infections 37
目次
Product Code: GBIHC033IDB

Abstract

  • Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018

Summary

  • RSV infects the lungs and breathing passages. Symptoms include cough, stuffy or runny nose, mild sore throat, earache and fever. There are 127 products in development for RSV infections and key companies operating in this pipeline space include Johnson & Johnson, MedImmune and ReViral.
  • HPIV-3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough runny nose, croup, bronchiolitis, wheezing and sore throat. There are five products in development for HPIV-3 infections and companies operating in this pipeline space include Ansun Biopharma and Amarillo Biosciences.
  • Molecular targets present in the RSV and HPIV-3 pipeline landscapes include exo alpha sialidase and fatty acid synthase.
  • This report "Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018" provides an overview of the pipeline landscape for the respiratory tract infections respiratory syncytial virus (RSV) and human parainfluenza virus 3 (HPIV-3). It comprehensively documents therapeutics under development for RSV and HPIV-3 infections, and features dormant and discontinued products.

Scope

  • Which companies are the most active within the pipeline for RSV and HPIV-3 infections?
  • Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1 Table of Contents 4

  • 1.1 List of Tables 5
  • 1.2 List of Figures 6

2 Introduction 8

  • 2.1 GBI Research Report Coverage 8
  • 2.2 Respiratory Syncytial Virus (RSV) Infections - Overview 8
  • 2.3 Human Parainfluenza Virus 3 Infections - Overview 8

3 Therapeutics Development 9

  • 3.1 Respiratory Syncytial Virus (RSV) Infections 9
  • 3.2 Human Parainfluenza Virus 3 Infections 22

4 Therapeutics Assessment 25

  • 4.1 Respiratory Syncytial Virus (RSV) Infections 25
  • 4.2 Human Parainfluenza Virus 3 Infections 31

5 Companies Involved in Therapeutics Development 38

  • 5.1 Respiratory Syncytial Virus (RSV) Infections 38
  • 5.2 Human Parainfluenza Virus 3 Infections 61

6 Dormant Projects 63

  • 6.1 Respiratory Syncytial Virus (RSV) Infections 63
  • 6.2 Human Parainfluenza Virus 3 Infections 67

7 Discontinued Products 68

  • 7.1 Respiratory Syncytial Virus (RSV) Infections 68
  • 7.2 Human Parainfluenza Virus 3 Infections 68

8 Product Development Milestones 69

  • 8.1 Respiratory Syncytial Virus (RSV) Infections 69

9 Appendix 81

  • 9.1 Methodology 81
  • 9.2 Coverage 81
  • 9.3 Secondary Research 81
  • 9.4 Primary Research 81
  • 9.5 Expert Panel Validation 81
  • 9.6 Contact Us 82
  • 9.7 Disclaimer 82
Back to Top